1. INTRODUCTION
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.4. Industry Value Chain Analysis
5. SOUTH KOREA ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY TYPE OF DISEASE
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
6. SOUTH KOREA ANTI-RHEUMATIC DRUG MARKET ANALYSIS, DRUG CLASS
6.1. Introduction
6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Corticosteroids
6.5. JAK inhibitor
6.6. Others
7. SOUTH KOREA ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. AbbVie Inc.
9.2. Amget Inc.
9.3. Johnson and Johnson
9.4. Pfizer Inc.
9.5. GlaxoSmithKline plc
9.6. Merck & Co., Inc.
9.7. Eli Lilly and Company
9.8. Novartis AG
9.9. Celgene Corporation (Bristol-Myers Squibb)